美托洛尔联合通心络对冠心病患者心率变异性的临床研究

Clinical study of metoprolol and tongxinluo on heart rate variability in patients with coronary heart disease

目的:探讨美托洛尔联合通心络治疗冠心病患者心率变异性(HRV)的临床效果。方法:选择2016年1月—2018年12月确诊并收治入院的冠心病患者120例,根据入院顺序编号随机分为对照组(n=60)和观察组(n=60)。对照组给予美托洛尔治疗,观察组给予美托洛尔联合通心络治疗,比较两组24 h平均心率、血压值、HRV、临床疗效及不良反应发生率。结果:治疗后观察组24 h平均心率、血压低于对照组,HRV高于对照组(P<0.05),差异均有统计学意义;治疗后观察组有效率高于对照组,差异有统计学意义(P<0.05)。结论:美托洛尔联合通心络能通过控制血压、心率水平改善HRV,提高临床疗效,减少不良反应。

Objective:Clinical study of metoprolol combined with Tongxinluo in the treatment of heart rate variability(HRV)in patients with coronary heart disease.Methods:All 120 patients with coronary heart disease in hospital from January 2016 to December 2018 were selected,and were randomly divided into two groups according to the order of admission,60 cases in each group.The control group was treated with metoprolol,while the observation group was treated with metoprolol combined with tongxinluo.The 24-hour average heart rate,blood pressure,HRV,clinical efficacy and incidence of adverse reactions were compared between groups.Results:After treatment,the 24-hour average heart rate and blood pressure in the observation group were lower than those in the control group(P<0.05).HRV in the observation group was higher than that in the control group(P<0.05).Tthe incidence of adverse reactions and clinical efficacy in the observation group were better than those in the control group(P<0.05).Conclusion:Application of metoprolol combined with tongxinluo can ameliorate HRV and reduce adverse reactions by controlling blood pressure and heart rate.